LONDON and SINGAPORE, November 24, 2022 (GLOBE NEWSWIRE) — Claritas HealthTech (“Claritas”)a health technology company specializing in medical image enhancement and artificial intelligence (AI)-assisted diagnostic tools, today announces that, following a rigorous review, it has been granted access to the National Covid-19 Chest Imaging Database (NCCID), curated by the AI Lab NHSE and peer review evaluation process to evaluate the benefits of iRADTM beyond modalities and conditions.
Claritas will conduct research using iRADTM, its Image Enhancement Software as a Medical Device (SaMD), with leading UK-based radiologists. The study will evaluate data across modalities (X-ray, CT and MRI) using multiple clinical, operational and quality parameters to benefit patient outcomes.
“Recognizing the need to evaluate the performance of new technologies using data representative of the population and treating physicians, Claritas has developed a study to evaluate the benefits of iRADTM with data representative of that population,‘ commented Dr. Arup Paul, Chief Clinical Strategy Officer at Claritas.
Parameters to be evaluated include optimization of technical image quality, improvements in clinical interpretation, lesion identification and the potential of these improved datasets to train more accurate AI tools to further assist clinicians and improve patient safety.
dr Paul added: “The evaluation of iRADTM Using the NCCID could provide benefits for patients and clinicians in multiple parts of the healthcare ecosystem, from screening programs to A&E to complex intervention planning.”
About Claritas HealthTech Ltd.
Claritas researches and develops in the fields of image enhancement, machine vision and artificial intelligence (“AI”) with a focus on medical image processing and AI-supported interpretation and diagnosis. Claritas aims to transform the diagnostics industry with powerful and effective software products developed using image enhancement and AI technology to enable and support physicians and medical professionals to make accurate diagnoses and improve patients’ lives. All Claritas are fully compliant with HIPPA, PDPA and GDPR requirements.
For more information, please visit www.claritashealthtech.com
For media inquiries please contact: